BioLargo Reports 55% Revenue Decline and $4 Million Net Loss in Q2 2026

BioLargo, Inc. reported a significant decline in financial performance for the second quarter of 2026, with total revenues of $1.25 million, a 55% decrease compared to $2.78 million in the same period of 2025. For the first half of 2026, revenues totaled $2.36 million, down 61% from $6.05 million in the prior year. The decline is attributed primarily to the cessation of sales of private-labeled pet odor control products, which previously accounted for a substantial portion of the company's revenue. Product revenues fell by 79% to $421,000 for the quarter, while service revenues increased by 7% to $827,000.

The company's net loss for the second quarter was $4 million, compared to a loss of $1.88 million in the same quarter of 2025. For the first half of 2026, the net loss reached $7.41 million, up from $3.80 million in the prior year. The increase in losses is largely due to reduced revenues and increased operating expenses, which rose to $4.4 million for the quarter, up from $3.22 million in the previous year. The company also reported a working capital deficit of $1.27 million as of June 30, 2026, with current liabilities of $4.77 million exceeding current assets of $3.50 million.

In terms of strategic developments, BioLargo has been actively pursuing financing options to support its operations and technology investments. The company entered into a purchase agreement with Clearthink Capital Partners, allowing it to sell up to $10 million in common stock over a 36-month period. As of June 30, 2026, BioLargo had raised $391,000 from the sale of 3.25 million shares under this agreement. Additionally, the company has been focusing on its subsidiaries, including Clyra Medical Technologies, which recently received its first purchase order for its ViaCLYR wound management solution.

Operationally, BioLargo's subsidiaries have shown mixed performance. ONM Environmental, which sells odor control products, experienced a 77% decline in revenue for the quarter, while BLEST, the engineering subsidiary, reported a slight increase in service revenues. Clyra Medical generated $154,000 in revenue for the first half of 2026, marking its first sales since inception. The company continues to invest in research and development, with R&D expenses increasing by 103% to $1.09 million for the quarter, reflecting ongoing efforts to advance its technologies.

Looking ahead, BioLargo faces challenges in achieving profitability and maintaining liquidity. The company anticipates that gross profits for the remainder of 2026 will not be sufficient to cover operational costs, necessitating further investment capital. Management has indicated that without additional funding or increased revenues, it may need to curtail operations. The outlook remains uncertain as the company navigates its financial difficulties while striving to commercialize its innovative technologies in environmental and medical sectors.